Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating
lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of
immunotherapy - a drug that is used to boost the ability of the immune system to fight
cancer, infection, and other diseases.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Bristol-Myers Squibb Iovance Biotherapeutics, Inc. Prometheus Inc. Stand Up To Cancer